<?xml version="1.0" encoding="UTF-8"?>
<p id="p0250">In addition, vaccines against SARS-CoV-2 are a classic and traditional choice. Currently, researchers around the world are working together to develop an effective vaccine. To date, there are 169 vaccines in the trial phase, 30 of which are in the clinical trial phase, with 6 in phase III, including a nonreplicating viral vector (ChAdOx1â€“5) from the University of Oxford (ISRCTN89951424), an RNA vaccine (LNP-encapsulated mRNA) from Moderna (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04470427" id="ir0005" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04470427</ext-link>), an RNA vaccine (LNP-mRNA) from BioNTech (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04368728" id="ir0010" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04368728</ext-link>), an inactivated vaccine from Sinovac (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04456595" id="ir0015" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04456595</ext-link>), and 2 inactivated vaccines from Sinopharm (ChiCTR2000034780). Additionally, Chen et al. announced the completion of the phase II clinical trial of Ad5-nCoV (ChiCTR2000031781) and are waiting to enter phase III.
</p>
